Harmony Biosciences Holdings, Inc. - 10-Q Filing
Harmony Biosciences Holdings filed its 10-Q for the quarter ended March 31, 2026, providing financial updates including revenue, expenses, and balance sheet details. The company reported $125.4 million in revenue for the first quarter of 2026, a 12% increase compared to $111.9 million in the same period in 2025. Net loss for the quarter was $18.7 million, or $0.23 per share, compared to a net loss of $15.2 million, or $0.19 per share, in the prior-year period.
Tickers: $HRMY